⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010979 | 1.00 | — | — | |
| SCHEMBL27471960 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2183314 | 0.97 | — | — | |
| SCHEMBL209221 | 0.81 | — | — | |
| SCHEMBL275234 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL25334514 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL4647423 | 0.77 | SLC7A5 (0.42) | — | |
| Ammonia Solution, Strong SCHEMBL4647428 | 0.77 | — | — | |
| SCHEMBL4648068 | 0.77 | — | — | |
| Bicarbonate SCHEMBL10985561 | 0.77 | SLC7A5 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113403287-B | Isolated polypeptides, nucleic acids and uses thereof | 中国农业大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-113403287-A | Isolated polypeptides, nucleic acids and uses thereof | 中国农业大学 | 2021-09-17 | — | — | CN | disclosed |
| EP-1990343-B1 | Azaindoles | AVENTIS PHARMA LTD (GB) | 2012-04-04 | — | — | EP | disclosed |
| EP-1616856-B1 | NOVEL TRANSCRIPTIONAL FACTOR, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | NRL PHARMA INC (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20110081678-A1 | METHOD FOR PRODUCING BETA-ALANYL-AMINO ACID OR DERIVATIVE THEREOF | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-1430018-B1 | METHOD FOR PRODUCING BETA-ALANINE AMIDES | LONZA AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265598-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | Sanofi-Aventis (FR) | 2010-12-29 | — | — | EP | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| JP-2010195793-A | METHOD FOR PRODUCING BETA-ALANINE AMIDES | LONZA AG | 2010-09-09 | — | — | JP | disclosed |
| WO-2003022795-A1 | METHOD FOR PRODUCING BETA-ALANINE AMIDES | LONZA AG (CH) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003001887-A2 | FUSED PYRIMIDINES AS D-ALANYL-D-ALANINE LIGASE INHIBITORS | ESSENTIAL THERAPEUTICS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| EP-1124882-A1 | PREPARATION OF CROSS-LINKED 2-DIMENSIONAL POLYMERS WITH SIDEDNESS FROM $g(a),$g(b)-LACTONES | MICHIGAN STATE UNIVERSITY (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
| US-6153724-A | A POLYLACTAM AS FLOCCULANTS IN WATER PURIFICATION, AS POLYMERS USEFUL ON NON-FOULING SURFACES FOR BIOFILM SUPPRESSION, THIN CONDUCTIVE FILMS FOR MICROCHIPS AND OTHER ELECTRONIC DEVICES | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000017254-A1 | PREPARATION OF CROSS-LINKED 2-DIMENSIONAL POLYMERS WITH SIDEDNESS FROM α,β-LACTONES | MICHIGAN STATE UNIVERSITY (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0866864-A2 | ANTIFUNGAL PROTEINS | ZENECA LIMITED (GB) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997021815-A2 | ANTIFUNGAL PROTEINS | ZENECA LIMITED (GB) | 1997-06-19 | — | — | WO | disclosed |